

Carbiotix receives a LinkGut clinical study order for 1 MSEK

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has received a LinkGut clinical study order for 1 MSEK from a leading microbiome science and consumer products company. This order represents Carbiotix first LinkGut clinical study order after recently achieving IVDR status for its LinkGut test kit. Payment for the order will be made in 2024 starting in Q1 when kits are sent out and ongoing as they are sent back and analyzed. Carbiotix will continue to ramp up commercial activities regarding its LinkGut service to microbiome science companies, Contract Research Organisations (CROs), and others interested in leveraging the advantages of the LinkGut microbiome testing service for clinical studies and research applications.

Erik Deaner, CEO of Carbiotix, comments:

"I am very excited to announce that Carbiotix has secured a LinkGut clinical study order valued at 1 MSEK from a leading microbiome science and consumer products company. Payment for the order will be made in 2024 starting in Q1 when kits are sent out and ongoing as they are sent back and analyzed. Following our achievement of IVDR status for our LinkGut test kit, this order represents a key milestone in expanding our potential LinkGut customer base. Initially focused on consumers through our B2B partnerships, we are now extending our reach to include clinical study and research applications. The latter segment represents approximately 90% of the 2 billion Euro global microbiome sequencing service market growing at a CAGR of over 20% [\(1\)](#).

This order is testament of the cost-advantages, flexibility and reliability that we achieved developing LinkGut as first a consumer service and later a B2B microbiome testing service. Our intention is to continue improving our LinkGut service for consumer, clinical and research applications. This will ensure that the service remains highly cost-competitive while holding up to the rigor expected from clinical studies and research applications.

I look forward to expanding our customer base across all applications and allowing these customers to leverage CarbiAXOS wherever possible as a complementary backbone prebiotic ingredient in their product development activities. This combined diagnostic and modulator offering will help usher in more efficacious microbiome products by fully embracing the trends of increased transparency and personalization. Moreover, it will solidify Carbiotix position as a key actor and broad-based technology partner within the global microbiome industry.

Forward-looking statements

This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company's contact person set out below on 29 February 2024.



Press Release
29 February 2024

For further information:

Carbiotix AB
Erik Deaner, CEO
Tel: +46 (0)738 67 30 85
E-mail: erik.deaner@carbiotix.com

Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services.